Contact Us
Drug Search Results
More Filters [+]

Bifonazole

Alternative Names: bifonazole
Latest Update: 2024-05-10
Latest Update Note: PubMed Publication

Product Description

It is a member of imidazoles and a member of biphenyls. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Bifonazole)

Mechanisms of Action: Ergosterol Synthesis Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Finland | France | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Korea | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Taiwan | Turkey | Ukraine | United Kingdom | Uruguay | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Bifonazole

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Tinea Pedis|Tinea Versicolor|Vulvovaginitis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
CTR20131282

P3

Active, not recruiting

Tinea Pedis|Vulvovaginitis|Tinea Versicolor

2015-02-13

Recent News Events

Date

Type

Title

05/10/2024

PubMed

 In vitro studies into establishing therapeutic bioequivalence of complex topical products: Weight of evidence.

05/03/2024

PubMed

 Bifonazole caffeate: The first molecular salt of bifonazole with enhanced biopharmaceutical property based on experiments and quantum chemistry research.

04/05/2024

PubMed

 Pathogenic Aspergillus Strains Identification and Antifungal Susceptibility Analysis of 452 Cases with Otomycosis in Jingzhou, China.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions